UOC
BOLT icon

UBS O'Connor’s Bolt Biotherapeutics BOLT Stock Holding History

UBS O'Connor’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-950
Closed -$625K – 880
2021
Q1 		$625K Buy
+950
New +$618K 0.01% 591

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

UBS O'Connor's BOLT Position: Q2 2021 in Review

UBS O'Connor sold out of Bolt Biotherapeutics (BOLT) in Q2 2021, closing a stake of 950 shares — an estimated $625K sold.

UBS O'Connor first reported a position in BOLT in Q1 2021 and held it in 1 quarter. The position peaked at $625K in Q1 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2021.

  • UBS O'Connor reported no remaining Bolt Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • UBS O'Connor sold 950 Bolt Biotherapeutics shares in Q2 2021, an estimated $625K.
  • UBS O'Connor first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 1 quarter.
  • UBS O'Connor's Bolt Biotherapeutics position peaked at $625K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2021.

Based on UBS O'Connor's 13F filing for Q2 2021, filed 13 Aug 2021.